Autoantibodies in cryptogenic fibrosing alveolitis

Respiratory Research

Ron du Bois¹  Suveer Singh¹ 

[1] Royal Brompton Hospital, Sydney Street, London, UK

关键词: pathogenesis;    idiopathic pulmonary fibrosis;    expression libraries;    cryptogenic fibrosing alveolitis;    autoantibodies;   

Others  :  1227462
DOI  :  10.1186/rr38

 received in 2001-01-31, accepted in 2001-02-02,  发布年份 2001

【 摘 要 】

The pathogenesis of cryptogenic fibrosing alveolitis (CFA) involves injury, an immune/inflammatory response and fibrosis. The cause of the injury is unknown, but the identification of serum autoantibodies makes an autoimmune aetiology attractive. The core study on which this commentary is based used novel cloning and serum screening technologies in order to identify new public and private autoantibodies in sera from 12 patients with CFA. Largely negative conclusions were drawn from that study. However, we suggest that the prevalence of autoantibodies may have been underestimated, that the study was timely and that this approach is worth pursuing further.

【 授权许可】

   
2001 BioMed Central Ltd

【 参考文献 】

• [1]Scadding JG: Fibrosing alveolitis [letter]. Br Med J 1964, 2:686.
• [2]American Thoracic Society : Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Amer-ican Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664.
• [3]Coultas DB, Zumwalt RE, Black WC, Sobonya RE: The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994, 150:967-973.
• [4]Panos RJ, Mortenson RL, Niccoli SA, King TE: Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990, 88:396-404.
• [5]Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA: Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997, 155:242-248.
• [6]Baumgartner KB, Samet JM, Coultas DB, Stidley CA, Hunt WC, Colby TV, Waldron JA: Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicentre case-control study. Collaborating Centres. Am J Epidemiol 2000, 152:307-315.
• [7]Hubbard R, Lewis S, Richards K, Johnston I, Britton J: Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996, 347:284-289.
• [8]Vergnon JM, Vincent M, DeThe G, Mornex JF, Weynants P, Brune P: Cryptogenic fibrosing alveolitis and Epstein–Barr virus: an association? Lancet 1984, 2:768-771.
• [9]Egan JJ, Woodcock AA, Stewart JP: Viruses and idiopathic pulmonary fibrosis. Eur Respir J 1997, 10:1433-1437.
• [10]Wangoo A, Shaw RJ, Diss TC, Farrell PJ, Du Bois RM, Nicholas AG: Cryptogenic fibrosing alveolitis: lack of association with Epstein–Barr virus infection. Thorax 1997, 52:888-891.
• [11]du Bois RM: Cryptogenic fibrosing alveolitis and cryptogenic organising pneumonia. In: Respiratory Medicine, 2nd ed. Edited by Brewis RAL, Corrin B, Geddes DM, Gibson GJ. London: Saunders; 1996, 1377-1393.
• [12]Katzenstein AL, Myers JL: Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998, 157:1301-1315.
• [13]Majumdar S, Li D, Ansari T, Pantelidis P, Black CM, Gizycki M, du Bois RM, Jeffery PK: Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999, 14:251-257.
• [14]Khalil N, O'Connor RN, Flanders KC, Unruh H: TGF-beta 1 but not TGF-beta 2 or TGF-beta 3 is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am J Respir Cell Mol Biol 1996, 14:131-138.
• [15]Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH: A preliminary study of long-term treatment with interferon Gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999, 341:1264-1269.
• [16]Turner Warwick M, Doniach D: Autoantibody studies in interstitial pulmonary fibrosis. Br Med J 1965, 1:886-891.
• [17]Chapman JR, Charles PJ, Venables PJ, Thompson PJ, Haslam PL, Maini RN, Turner-Warwick ME: Definition and clinical relevance of antibodies to nuclear ribonucleoprotein and other nuclear antigens in patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1984, 130:439-443.
• [18]Meliconi R, Bestagno M, Sturani C, Negri C, Galavotti V, Sala C, Facchini A, Ciarrocchi G, Gasbarrini G, Astaldi Ricotti GC: Autoantibodies to DNA topoisomerase II in cryptogenic fibrosing alveolitis and connective tissue disease. Clin Exp Immunol 1989, 76:184-189.
• [19]Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Tokuda M, Hojo S, Bandou S, Ueda Y, Takahara J: Circulating cytokeratin 8:anti-cytokeratin 8 antibody immune complexes in sera of patients with pulmonary fibrosis. Respiration 2000, 67:397-401.
• [20]Dreisen RB, Schwarz MI, Theofilopoulos AN, Stanford RE: Circulating immune complexes in the idiopathic interstitial pneumonias. N Engl J Med 1978, 298:353-358.
• [21]Dall'Aglio PP, Pesci A, Bertorelli G, Brianti E, Scarpa S: Study of immune complexes in bronchoalveolar lavage fluids. Respiration 1988, 54 (suppl 1):36-41.
• [22]Wallace WA, Roberts SN, Caldwell H, Thornton E, Greening AP, Lamb D, Howie SE: Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis. Thorax 1994, 49:218-222.
• [23]Wallace WA, Schofield JA, Lamb D, Howie SE: Localisation of a pulmonary autoantigen in cryptogenic fibrosing alveolitis. Thorax 1994, 49:1139-1145.
• [24]Robinson C, Callow M, Stevenson S, Robinson BWS, Lake RA: Private specificities can dominate the humoral response to self-antigens in patients with cryptogenic fibrosing alveolitis. Respiratory Research 2001, in press.
• [25]Robinson C, Callow M, Stevenson S, Scott BS, Robinson BWS, Lake RA: Serologic responses in patients with malignant mesothelioma. Evidence for both public and private specificities. Am J Respir Cell Biol 2000, 22:550-556.